Erschienen in:
06.07.2021 | Original Article
Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis
verfasst von:
Munehisa Bekki, MD, Nobuhiro Tahara, MD, PhD, Atsuko Tahara, MD, Yoichi Sugiyama, MD, PhD, Shoko Maeda-Ogata, MD, Akihiro Honda, MD, PhD, Sachiyo Igata, MD, Mika Enomoto, MD, PhD, Tatsuyuki Kakuma, MPH, PhD, Hayato Kaida, MD, PhD, Toshi Abe, MD, PhD, Yoshihiro Fukumoto, MD, PhD
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 5/2022
Einloggen, um Zugang zu erhalten
Abstract
Background
The localization of myocardial 18F-fluorodeoxyglucose (FDG) uptake affecting long-term clinical outcomes has not been elucidated in patients with corticosteroid-naïve cardiac sarcoidosis (CS).
Objectives
This study sought to investigate the localization of myocardial FDG uptake on positron emission tomography (PET) and myocardial perfusion abnormality to predict adverse events (AEs) for a long-term follow-up in patients with corticosteroid-naïve CS.
Methods
Consecutive 90 patients with clinical suspicion of CS who underwent FDG-PET imaging to assess for inflammation were enrolled. AEs were defined as a composite of sustained ventricular tachycardia (VT), heart transplantation, and all-cause death, which were ascertained by medical records, defibrillator interrogation, and telephone interviews.
Results
Of 90 patients, 42 patients (mean age 62.9 ± 12.0 years; 76.2% females) were confirmed active cardiac involvement. Over a median follow-up of 4.9 years, 15 patients with CS experienced AEs including 6 sustained ventricular tachycardias (VT) and 9 deaths. Cox proportional-hazards model after adjustment for left ventricular systolic dysfunction revealed that FDG uptake in the right ventricle (RV) or basal anterolateral area of the left ventricle (LV) with myocardial perfusion abnormality was predictive of AEs.
Conclusions
FDG uptake in the RV or basal anterolateral area of the LV with myocardial perfusion abnormality provides long-term prognostic risk stratification in patients with corticosteroid-naïve CS.